Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease [Yahoo! Finance]
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
Gain Therapeutics (NASDAQ:GANX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Gain Therapeutics (NASDAQ:GANX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.